Horizon Pharma plc and privately held biotechnology company HemoShear Therapeutics LLC have entered a collaboration agreement to discover and develop novel therapeutics for gout, a type of arthritis.
Gout is characterized as a chronic, progressive inflammatory form of arthritis that is caused by excess uric acid in the body, which can lead to severe pain, tenderness, stiffness, swelling and joint damage.
Under the agreement, HemoShear will receive up front payments and funding for research and development, and Horizon will receive exclusive access to HemoShear's proprietary disease modeling platform, named REVEAL-Tx, to discover new therapeutics for the disease.
REVEAL-Tx combines physiological and computational models of disease to identify novel treatment approaches and select drug candidates in a human-relevant disease context, according to a Jan. 3 news release.
In case the Dublin-based biopharmaceutical company successfully develops and commercializes multiple therapies, HemoShear will be eligible to receive milestone payments of more than $500 million as well as royalties.
Additional financial terms of the agreement were not disclosed.
Charlottesville, Va.-based HemoShear discovers novel biological targets and drugs to treat a range of metabolic disorders that have a significant unmet patient need.